Cleo Breast
Your personal AI assistant in the battle against breast cancer
Software · Cloud SaaSCompany source
Company profile
About Primaa
Founded in 2018, Primaa is a MedTech company offering an AI-based platform for automated and accurate cancer diagnosis in digital pathology. The company develops AI-powered software capable of detecting all cancer biomarkers with high speed and great accuracy, leveraging image analysis and deep learning technology. Primaa's solutions are designed by pathologists, for pathologists, focusing on improving the detection of major cancer biomarkers and guiding personalized treatment decisions. Their platform empowers pathologists with time-saving capabilities, accelerating case reviews and providing faster diagnoses through intelligent triage and case prioritization. The company's technology enhances diagnostic precision and confidence while advancing personalized medicine with more precise patient data. Primaa has developed the world's first CE-IVDR marked AI solution for dermatopathology and offers specialized tools for breast cancer diagnosis. Their solutions combine medical expertise with scientific validation to create clinically relevant applications that streamline pathology workflows and improve patient outcomes.
Company description Primaa official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Primaa?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- basal-cell carcinoma
- breast cancer
- dermatopathology
- invasive carcinoma
- melanoma
- skin cancer
- squamous-cell carcinoma
Who it serves
- diagnostic laboratories
- hospitals
- pathologists
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEurope
Company sourceOfficial website
Company milestones
Platform expansion
March 2025: Partnership with Gestalt to revolutionize skin cancer detection. World's first CE-IVDR marked AI solution for dermatopathology launched. Multiple scientific publications in 2023-2025.
Partnerships
Recorded partners
- Gestalt
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Cleo Skin
The world's first CE-IVDR marked AI solution for dermatopathology
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Evaluating AI-Based Mitosis Detection for Breast Carcinoma in Digital Pathology: A Clinical Study on Routine Practice Integration.Diagnostics (Basel, Switzerland) · Apr 28, 2025
Standardized CycleGAN training for unsupervised stain adaptation in invasive carcinoma classification for breast histopathology.Journal of medical imaging (Bellingham, Wash.) · Nov 1, 2023
Multicenter automatic detection of invasive carcinoma on breast whole slide images.PLOS digital health · Feb 1, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
time-saving
accelerate case reviews and provide faster diagnoses
diagnostic precision
greater precision and confidence in diagnosis making
workflow efficiency
smart work list with intelligent triage and case prioritization
Gestalt
Collaboration to revolutionize skin cancer detection using AI-based dermatopathology solutions
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Primaa
Recent articles published on Primaa's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.